New therapeutic approaches in inflammatory bowel disease.
This article surveys the current thrust of the 'new therapeutics' of inflammatory bowel disease. It defines the potential targets of therapy-enhancing the mucosal barrier between mucosa and lumen, altering the antigen challenge from the lumen, and inhibiting the processes leading to amplification and recruitment of pro-inflammatory mechanisms. Approaches based on current understanding of the molecular aspects of inflammation are emphasised, including the use of monoclonal antibodies, cytokine receptor antagonists, and rapidly metabolised corticosteroids.
Hodgson
H J
HJ
Royal Postgraduate Medical School London, Hammersmith Hospital, UK.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000276:immunology; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000628:therapy*; D007413:Intestinal Mucosa / Q000276:immunology; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018121:Receptors, Cytokine